logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Dirk Klingbiel

Kantonsspital St. Gallen
H指数:35
被引数:5,585

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

PERUSE一线帕妥珠单抗加曲妥珠单抗加紫杉烷治疗HER2-positive局部复发或转移性乳腺癌的最终结果，采用多变量方法指导预后

ANNALS OF ONCOLOGY
IF65.4
2021-10-0143
OAAI
Miles, D.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Campone, M.; Bondarenko, I.; Nowecki, Z.; Errihani, H.; Paluch-Shimon, S.; Wardley, A.; Merot, J. -l.; Trask, P.; du Toit, Y.; Pena-Murillo, C.; Revelant, V.; Klingbiel, D.; Bachelot, T.
Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

HER2-positive早期乳腺癌患者皮下注射帕妥珠单抗和曲妥珠单抗的固定剂量组合的原始研究偏好 (PHranceSCa): 一项随机，开放标签的II期研究

EUROPEAN JOURNAL OF CANCER
IF7.1
2021-07-0131
OAAI
O'Shaughnessy, Joyce; Sousa, Susana; Cruz, Josefina; Fallowfield, Lesley; Auvinen, Paivi; Pulido, Catarina; Cvetanovic, Ana; Wilks, Sharon; Ribeiro, Leonor; Burotto, Mauricio; Klingbiel, Dirk; Messeri, Dimitri; Alexandrou, Ari; Trask, Peter; Fredriksson, Judy; Machackova, Zuzana; Stamatovic, Ljiljana
Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
ANNALS OF ONCOLOGY
IF65.4
2020-09-019
OAAI
O'Shaughnessy, J.; Sousa, S.; Cruz, J.; Fallowfield, L.; Auvinen, P.; Pulido, C.; Cvetanovic, A.; Wilks, S.; Ribeiro, L.; Burotto, M.; Klingbiel, D.; Messeri, D.; Alexandrou, A.; Trask, P.; Fredriksson, J.; Machackova, Z.; Stamatovic, L.
Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
ANNALS OF ONCOLOGY
IF65.4
2020-05-010
OAAI
O'Shaughnessy, J.; Sousa, S. P.; Cruz, J.; Fallowfield, L. J.; Auvinen, P.; Pulido, C.; Cvetanovic, A.; Wilks, S.; Ribeiro, L.; Burotto, M.; Klingbiel, D.; Messeri, D.; Alexandrou, A.; Trask, P.; Fredriksson, J.; Stamatovic, L.
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

新辅助放疗联合卡培他滨和索拉非尼治疗晚期KRAS突变直肠癌的I/II期临床试验 (SAKK 41/08)

EUROPEAN JOURNAL OF CANCER
IF7.1
2018-01-0120
PREAI
von Moos, Roger; Koeberle, Dieter; Schacher, Sabina; Hayoz, Stefanie; Winterhalder, Ralph C.; Roth, Arnaud; Bodoky, Gyorgy; Samaras, Panagiotis; Berger, Martin D.; Rauch, Daniel; Saletti, Piercarlo; Plasswilm, Ludwig; Zwahlen, Daniel; Meier, Urs R.; Yan, Pu; Izzo, Paola; Klingbiel, Dirk; Bartschi, Daniela; Zaugg, Kathrin

研究方向

暂未获取到该数据
R
Roger von Moos
H 指数:49论文数:397被引数:9,524
R
Richard Cathomas
H 指数:43论文数:337被引数:1.2万
S
Stephan Bodis
H 指数:38论文数:177被引数:6,996
T
Thomas Ruhstaller
H 指数:38论文数:170被引数:6,510
C
Christoph Mamot
H 指数:28论文数:98被引数:5,290
N
Niloy R. Datta
H 指数:26论文数:150被引数:3,168
P
Peter Brauchli
H 指数:24论文数:66被引数:2,013
P
Peter C. Trask
H 指数:37论文数:209被引数:6,063
B
Beat Thürlimann
H 指数:71论文数:494被引数:3.9万
M
Mauro Delorenzi
H 指数:86论文数:439被引数:4.2万